Serological and Cellular Response to mRNA-SARS-CoV2 Vaccine in Patients With Hematological Lymphoid Malignancies: Results of the Study “Cervax”

Development and Validation of a Novel TNM Staging N-Classification of Oral Cavity Squamous Cell Carcinoma

Utilizing Biomarkers to Optimize Treatment for Upper Gastrointestinal Cancers

Survival Benefit With Checkpoint Inhibitors Versus Chemotherapy is Modified by Brain Metastases in Patients With Recurrent Small-Cell Lung Cancer

Evaluating Strategies and Approaches to Prevent Graft-Versus-Host Disease

ChatGPT's Limited Ability to Recommend Guideline-Based Cancer Treatments

Response Assessment of Post-Treatment Head and Neck Cancers to Determine Further Management Using NI-RADS (Neck Imaging Reporting and Data System): A Subgroup Analysis of a Randomized Controlled Trial

IDEAYA Biosciences Receives Fast Track Designation for IDE161 in a Second Indication for the Treatment of Pretreated, Advanced or Metastatic HR+, HER2-, BRCA1/2 Mutant Breast Cancer

Serological and Cellular Response to mRNA-SARS-CoV2 Vaccine in Patients With Hematological Lymphoid Malignancies: Results of the Study “Cervax”

header-info

Mar, 01, 2023

Researchers report results from the prospective, unicentric, observational CERVAX study, which aimed to assess the overall serological and T-cell mediated response to the BNT162b2 vaccine in a cohort of COVID negative, hematology patients with various lymphomas.

Access the full article to read more here.